Short Interest in BriaCell Therapeutics Corp. (NASDAQ:BCTX) Expands By 28.7%

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the target of a large growth in short interest in November. As of November 30th, there was short interest totalling 688,400 shares, a growth of 28.7% from the November 15th total of 534,800 shares. Based on an average daily volume of 5,250,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 2.1% of the shares of the stock are short sold.

BriaCell Therapeutics Stock Performance

Shares of BCTX stock remained flat at $0.66 during mid-day trading on Friday. The stock had a trading volume of 2,234,086 shares, compared to its average volume of 1,642,969. The firm has a market capitalization of $23.88 million, a P/E ratio of -0.56 and a beta of 1.46. BriaCell Therapeutics has a twelve month low of $0.46 and a twelve month high of $5.97. The firm’s 50-day moving average is $0.84 and its 200-day moving average is $0.89.

BriaCell Therapeutics (NASDAQ:BCTX) last issued its quarterly earnings data on Monday, October 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.45. On average, equities analysts forecast that BriaCell Therapeutics will post -1.01 EPS for the current fiscal year.

Institutional Trading of BriaCell Therapeutics

An institutional investor recently bought a new position in BriaCell Therapeutics stock. Vontobel Holding Ltd. acquired a new stake in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned 0.44% of BriaCell Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 15.42% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of BriaCell Therapeutics in a research note on Thursday.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.